Jaguar Health Announces $1.5M Direct Stock Offering

Jaguar Animal Health ( (JAGX) ) has shared an update.

On May 20, 2025, Jaguar Health, Inc. entered into a securities purchase agreement for a registered direct offering of 246,306 shares of common stock at $6.09 per share, expected to raise approximately $1.5 million. The offering, set to close around May 22, 2025, includes a concurrent private placement of unregistered warrants to purchase up to 492,612 shares. The proceeds will be used for corporate purposes, including working capital and debt repayment. H.C. Wainwright & Co. acted as the placement agent, receiving a fee and warrants as compensation. This move is part of Jaguar’s strategy to strengthen its financial position and support its operational and development goals.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.

Jaguar Animal Health’s stock score is low due to substantial financial difficulties, characterized by high leverage, negative profitability, and bearish technical indicators. While there is some optimism from earnings calls and corporate events, persistent financial instability and clinical trial challenges weigh heavily on the stock’s potential.

To see Spark’s full report on JAGX stock, click here.

More about Jaguar Animal Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines derived from plants in rainforest areas for treating gastrointestinal distress in humans and animals. Its subsidiary, Napo Pharmaceuticals, develops human prescription pharmaceuticals for managing neglected gastrointestinal symptoms, with crofelemer being FDA-approved for noninfectious diarrhea in adults with HIV/AIDS. Napo Therapeutics, based in Milan, Italy, aims to expand crofelemer access in Europe, particularly for orphan and rare diseases. Additionally, Jaguar has a joint venture, Magdalena Biosciences, focused on plant-derived medicines for mental health.

Average Trading Volume: 125,439

Technical Sentiment Signal: Sell

Current Market Cap: $5.95M

For a thorough assessment of JAGX stock, go to TipRanks’ Stock Analysis page.